Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Enzo Biochem Inc is a diagnostics & research business based in the US. Enzo Biochem shares (ENZ) are listed on the NYSE and all prices are listed in US Dollars. Enzo Biochem employs 451 staff and has a trailing 12-month revenue of around $111.6 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $2.37 |
|---|---|
| 52-week range | $1.98 - $4.15 |
| 50-day moving average | $2.44 |
| 200-day moving average | $2.73 |
| Wall St. target price | $5.50 |
| PE ratio | 5.4974 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.14 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.37 from 2022-10-03
| 1 week (2022-09-27) | 12.86% |
|---|---|
| 1 month (2022-09-01) | N/A |
| 3 months (2022-07-01) | N/A |
| 6 months (2022-04-05) | -19.66% |
| 1 year (2021-10-05) | -32.09% |
|---|---|
| 2 years (2020-10-05) | 7.24% |
| 3 years (2019-10-04) | 3.52 |
| 5 years (2017-10-04) | 10.5 |
Valuing Enzo Biochem stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enzo Biochem's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enzo Biochem's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Enzo Biochem shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $111.6 million |
|---|---|
| Gross profit TTM | $53.6 million |
| Return on assets TTM | -6.02% |
| Return on equity TTM | -1031.82% |
| Profit margin | -5.88% |
| Book value | $1.28 |
| Market capitalisation | $108.6 million |
TTM: trailing 12 months
We're not expecting Enzo Biochem to pay a dividend over the next 12 months.
Enzo Biochem's shares were split on a 105:100 basis on 20 October 2004. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your Enzo Biochem shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Enzo Biochem shares which in turn could have impacted Enzo Biochem's share price.
Over the last 12 months, Enzo Biochem's shares have ranged in value from as little as $1.98 up to $4.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enzo Biochem's is 0.8546. This would suggest that Enzo Biochem's shares are less volatile than average (for this exchange).
Enzo Biochem, Inc. , an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.